Compare GAUZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | MGNX |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 94.9M |
| IPO Year | 2024 | 2013 |
| Metric | GAUZ | MGNX |
|---|---|---|
| Price | $1.16 | $1.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $11.50 | $3.20 |
| AVG Volume (30 Days) | 294.3K | ★ 1.4M |
| Earning Date | 03-11-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $96,810,000.00 | ★ $127,626,000.00 |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $47.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.87 | N/A |
| 52 Week Low | $0.95 | $0.99 |
| 52 Week High | $13.00 | $3.60 |
| Indicator | GAUZ | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 26.52 | 59.83 |
| Support Level | $0.95 | $1.32 |
| Resistance Level | $1.32 | $1.45 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 11.80 | 84.85 |
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.